Treatment of tuberculosis in HIV-infected patients: We need to know more

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 11, 2007, Pages 1102-1103

  Perlman, David C ^a   Chi, Chiu Leung ^b   Wing, Wai Yew ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b DEPARTMENT OF HEALTH   (Hong Kong)

^c GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL PLUS ISONIAZID; ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAPENTINE;

BACTERIAL GROWTH; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; SHORT COURSE THERAPY; SPUTUM CULTURE; TREATMENT FAILURE; TUBERCULOSIS CONTROL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; MICE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34249828402     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200702-248ED     Document Type: Editorial

References (17)

1. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001;32:623-632.
2. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Masae Kawamura L, Osmond DH, Hopewell PC, Daley CL. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175:1199-1206.
3. American Thoracic Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
4. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame JC, Mandala JK, Kaboto M, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-784.
5. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, et al. Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIVrelated tuberculosis. Am J Respir Crit Care Med 2006;173:350-356.
6. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005;41:83-91.
7. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo V, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580.
8. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA. AIDS Clinical Trials Group 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIVinfected persons with tuberculosis. Clin Infect Dis 2005;41:1638-1647.
9. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T. Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharamacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-1491.
10. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847.
11. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, et al. Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-1197.
12. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-135.
13. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentinecontaining regimens in murine tuberculosis. Am J Respir Crit Care Med 2006;174:94-101.
14. Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, Mosher A, Samuels M, Vernon A. Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002;165: 1526-1530.
15. Khan A, Sterling TR, Reves R, Vernon A, Horsburgh CR. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med 2006;174:344-348.
16. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/ tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:42-46.
17. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117:744-751.